Virani SS, Alonso A, Aparicio HJ, et al. Heart disease and stroke statistics-2021 update: a report from the American Heart Association. Circulation. 2021;143(8):e254–743. https://doi.org/10.1161/CIR.0000000000000950.

Article  Google Scholar 

Johnson NB, Hayes LD, Brown K, et al. CDC National Health Report: leading causes of morbidity and mortality and associated behavioral risk and protective factors—United States, 2005–2013. MMWR Suppl. 2014;63(4):3–27.

Google Scholar 

Chobufo MD, Singla A, Rahman EU, Michos ED, Whelton PK, Balla S. Temporal trends in atherosclerotic cardiovascular disease risk among US adults. Analysis of the National Health and Nutrition Examination Survey, 1999–2018. Eur J Prev Cardiol. 2022;29(18):2289–300. https://doi.org/10.1093/eurjpc/zwac161.

Article  Google Scholar 

Chobufo MD, Regner SR, Zeb I, Lacoste JL, Virani SS, Balla S. Burden and predictors of statin use in primary and secondary prevention of atherosclerotic vascular disease in the US: from the National Health and Nutrition Examination Survey 2017–2020. Eur J Prev Cardiol. 2022;29(14):1830–8. https://doi.org/10.1093/eurjpc/zwac103.

Article  Google Scholar 

Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–77. https://doi.org/10.1093/eurheartj/ehz425.

Article  Google Scholar 

Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S49-73. https://doi.org/10.1161/01.cir.0000437741.48606.98.

Article  Google Scholar 

Force USPST, Davidson KW, Barry MJ, et al. Aspirin use to prevent cardiovascular disease: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;327(16):1577–84. https://doi.org/10.1001/jama.2022.4983.

Article  Google Scholar 

ASCEND Study Collaborative Group, Bowman L, Mafham M, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379(16):1529–39. https://doi.org/10.1056/NEJMoa1804988.

Article  Google Scholar 

McNeil JJ, Wolfe R, Woods RL, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med. 2018;379(16):1509–18. https://doi.org/10.1056/NEJMoa1805819.

Article  Google Scholar 

Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):e596–646. https://doi.org/10.1161/CIR.0000000000000678.

Article  Google Scholar 

Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392(10152):1036–46. https://doi.org/10.1016/S0140-6736(18)31924-X.

Article  Google Scholar 

Hall HM, de Lemos JA, Enriquez JR, et al. Contemporary patterns of discharge aspirin dosing after acute myocardial infarction in the United States: results from the National Cardiovascular Data Registry (NCDR). Circ Cardiovasc Qual Outcomes. 2014;7(5):701–7. https://doi.org/10.1161/CIRCOUTCOMES.113.000822.

Article  Google Scholar 

Medical Expenditure Panel Survey. An official website of the Department of Health & Human Services. https://meps.ahrq.gov/mepsweb/. Accessed 25 Feb 2024.

Force USPST. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med. 2002;136(2):157–60. https://doi.org/10.7326/0003-4819-136-2-200201150-00015.

Article  Google Scholar 

US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;150(6):396–404. https://doi.org/10.7326/0003-4819-150-6-200903170-00008.

Article  Google Scholar 

Bibbins-Domingo K, US Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: US Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016;164(12):836–45. https://doi.org/10.7326/M16-0577.

Article  Google Scholar 

Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007;14(Suppl 2):E1–40. https://doi.org/10.1097/01.hjr.0000277984.31558.c4.

Article  Google Scholar 

Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33(13):1635–701. https://doi.org/10.1093/eurheartj/ehs092.

Article  Google Scholar 

Smith SC Jr, Blair SN, Bonow RO, et al. AHA/ACC Guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol. 2001;38(5):1581–3. https://doi.org/10.1016/s0735-1097(01)01682-5.

Article  Google Scholar 

Fleg JL, Forman DE, Berra K, et al. Secondary prevention of atherosclerotic cardiovascular disease in older adults: a scientific statement from the American Heart Association. Circulation. 2013;128(22):2422–46. https://doi.org/10.1161/01.cir.0000436752.99896.22.

Article  Google Scholar 

Centers for Medicare & Medicaid Services, Hospital Readmissions Reduction Program (HRRP). https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Readmissions-Reduction-Program. Accessed 25 July 2023.

Desai NR, Udell JA, Wang Y, et al. Trends in performance and opportunities for improvement on a composite measure of acute myocardial infarction care. Circ Cardiovasc Qual Outcomes. 2019;12(3): e004983. https://doi.org/10.1161/CIRCOUTCOMES.118.004983.

Article  Google Scholar 

Jones WS, Mulder H, Wruck LM, et al. Comparative effectiveness of aspirin dosing in cardiovascular disease. N Engl J Med. 2021;384(21):1981–90. https://doi.org/10.1056/NEJMoa2102137.

Article  Google Scholar 

Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86. https://doi.org/10.1136/bmj.324.7329.71.

Article  Google Scholar 

Ansa BE, Hoffman Z, Lewis N, et al. Aspirin use among adults with cardiovascular disease in the United States: implications for an intervention approach. J Clin Med. 2019. https://doi.org/10.3390/jcm8020264.

Article  Google Scholar 

Opotowsky AR, McWilliams JM, Cannon CP. Gender differences in aspirin use among adults with coronary heart disease in the United States. J Gen Intern Med. 2007;22(1):55–61. https://doi.org/10.1007/s11606-007-0116-5.

Article  Google Scholar 

Boakye E, Uddin SMI, Obisesan OH, et al. Aspirin for cardiovascular disease prevention among adults in the United States: trends, prevalence, and participant characteristics associated with use. Am J Prev Cardiol. 2021;8:100256. https://doi.org/10.1016/j.ajpc.2021.100256.

Article  Google Scholar 

Zhao M, Woodward M, Vaartjes I, et al. Sex differences in cardiovascular medication prescription in primary care: a systematic review and meta-analysis. J Am Heart Assoc. 2020;9(11):e014742. https://doi.org/10.1161/JAHA.119.014742.

Article  Google Scholar 

Luepker RV, Oldenburg NC, Misialek JR, et al. Aspirin use and misuse for the primary prevention of cardiovascular diseases. Am J Prev Med. 2021;60(4):513–9. https://doi.org/10.1016/j.amepre.2020.10.025.

Article  Google Scholar 

Bazargan M, Wisseh C, Adinkrah E, Boyce S, King EO, Assari S. Low-dose aspirin use among African American older adults. J Am Board Fam Med. 2021;34(1):132–43. https://doi.org/10.3122/jabfm.2021.01.200322.

Article  Google Scholar 

Ashraf M, Jan MF, Bajwa TK, Carnahan R, Zlochiver V, Allaqaband SQ. Sex disparities in diagnostic evaluation and revascularization in patients with acute myocardial infarction—a 15-year nationwide study. J Am Heart Assoc. 2023;12(6):e027716. https://doi.org/10.1161/JAHA.122.027716.

Article  Google Scholar 

Drai E, Marques-Vidal P, Bochud M, Vaucher J. Temporal trends in low-dose aspirin use (from the CoLaus|PsyCoLaus Study). Am J Cardiol. 2023;190:61–6. https://doi.org/10.1016/j.amjcard.2022.11.037.

Article  Google Scholar 

Kristensen AMD, Pareek M, Kragholm KH, Torp-Pedersen C, McEvoy JW, Prescott EB. Temporal trends in low-dose aspirin therapy for primary prevention of cardiovascular disease in European adults with and without diabetes. Eur J Prev Cardiol. 2023. https://doi.org/10.1093/eurjpc/zwad092.

Article  Google Scholar 

Josefson D. Bayer made to tone down aspirin advertisements. West J Med. 2000;172(3):154. https://doi.org/10.1136/ewjm.172.3.154.

Article  Google Scholar 

Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–81. https://doi.org/10.1093/eurheartj/ehw106.

Article  Google Scholar 

Hira RS, Gosch KL, Kazi DS, et al. Potential impact of the 2019 ACC/AHA guidelines on the primary prevention of cardiovascular disease recommendations on the inappropriate routine use of aspirin and aspirin use without a recommended indication for primary prevention of cardiovascular disease in cardiology practices: insights from the NCDR PINNACLE Registry. Circ Cardiovasc Qual Outcomes. 2022;15(3): e007979. https://doi.org/10.1161/CIRCOUTCOMES.121.007979.

Article  Google Scholar 

Rhee TG, Kumar M, Ross JS, Coll PP. Age-related trajectories of cardiovascular risk and use of aspirin and statin among US adults aged 50 or older, 2011–2018. J Am Geriatr Soc. 2021;69(5):1272–82. https://doi.org/10.1111/jgs.17038.

Article  Google Scholar